ConductScience.org, home

Comparison · NCT00953927-9eb1a003

Investigational Vaccine vs Control Group: To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Investigational Vaccine vs Control Group: To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial. Trial comparisons, record NCT00953927-9eb1a003. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00953927-9eb1a003

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1270.1110.146wilson
Risk in group 20.1230.1060.141wilson
Risk difference, group 1 minus group 20.00466-0.01990.0292newcombe hybrid score
Risk ratio, group 1 over group 21.040.8531.26log
Odds ratio, group 1 over group 21.040.8341.31log
Number needed to treat, for one more participant with the outcome on Investigational Vaccine than on Control Group215from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: control.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Investigational VaccineMVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.1781,398OG000
Group 2Control GroupCandida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.1711,394OG001

Outcome

Type
SECONDARY
Title
To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial.
Description
The number (percentage) of infants with QuantiFERON conversions at any time on the study were summarized by treatment group.
Time frame
15 to 36 months post-vaccination
Population
Per protocol population who were quantiferon negative at baseline.

Source ClinicalTrials.gov

Trial

Title
A Study of MVA85A in Healthy Infants
NCT number
NCT00953927
Phases
PHASE2
Conditions
Tuberculosis
Interventions
MVA85A/AERAS-485, Candida Skin Test Antigen
Lead sponsor
Aeras
Results first posted
2013-12-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00953927-9eb1a003